Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01006889|
Recruitment Status : Completed
First Posted : November 3, 2009
Results First Posted : July 29, 2016
Last Update Posted : September 28, 2016
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled patients with type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
Secondary aims are to learn: 1) the efficacy and safety of such approach and whether it is an acceptable treatment strategy compared to intensified insulin therapy alone; 2) mechanisms of action (effects on insulin secretion and insulin action); 3) its impact on weight (can it prevent insulin-associated weight gain or cause weight loss) and rates of hypoglycemia; 4) if it may improve specific plasma biomarkers of disease activity in NAFLD and inflammatory markers common to both conditions - T2DM and NAFLD (hsCRP, ICAM, VCAM).
|Condition or disease||Intervention/treatment||Phase|
|Nonalcoholic Fatty Liver Disease Type 2 Diabetes Mellitus||Drug: Exenatide||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||December 2009|
|Actual Study Completion Date :||February 2010|
Experimental: Exenatide (twice daily)
Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
Other Name: Byetta
- Hepatic Steatosis [ Time Frame: 6 months ]Hepatic steatosis was assessed non-invasively by MRS.
- A1c [ Time Frame: 6 months ]Patients with controlled T2DM with bedtime insulin alone (n=5) or bedtime insulin and premeal rapid-acting insulin novolog (n=15) had eventide given twice daily for 6 months (if on premeal insulin it was stopped). The goal is to assess if adding SQ exenatide is effective to maintain optimal glycemic control in this population.
- Change in Anthropometric Variables (Weight). [ Time Frame: 6 months ]
- Number of Severe Hypoglycemic (Glucose ≤40 mg/dL) Events. [ Time Frame: 6 months ]
- Insulin Secretion (Hyperglycemic Clamp) [ Time Frame: 6 months ]Change in C-peptide levels vs. pretreatment in the first and second phase.
- Percent Change From Baseline in Glucose Infusion (M Value) During Hyperglycemic Clamp [ Time Frame: 6 months ]M value represents glucose infusion change
- Lipid Profiles, Lipoprotein Analysis by NMR (LipoScience). [ Time Frame: 6 months ]Change in lipid levels vs. pretreatment.
- Change in Anthropometric Variables (BMI). [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006889
|United States, Texas|
|The University of Texas H.S.C. at San Antonio and the San Antonio Audie L. Murphy VA Hospital|
|San Antonio, Texas, United States, 78229-3900|
|Principal Investigator:||Kenneth Cusi, M.D.||University of Florida|